Forecast

The analysts' average price target is €51.31 (+148.23%). The median is €51.31 (+148.23%).

Buy	18
Hold	8
Sell	1

News Go to news feed

Beam Therapeutics emphasizes leadership in base editing and shows positive BEAM‑302 data

Beam Therapeutics presented promising clinical data for the in‑vivo BEAM‑302 program in alpha‑1 antitrypsin deficiency at the Cantor conference, with the 60 mg dose reaching the protective threshold in all patients. The company reported $1.2 billion in cash with a financial runway to mid‑2029 and plans multiple launches, including Risto‑cel with a possible BLA filing and launch in the second half of 2027. Beam highlighted its integrated manufacturing infrastructure and an alleged lead of more than two years in base editing, but acknowledged safety monitoring (a transient grade‑3 liver enzyme increase) and intense competitive pressure. » More on de.investing.com
Beam Therapeutics presents progress of base‑editing platform at Citigroup conference

Beam Therapeutics reported comprehensive advances across its base‑editing pipeline, including an expected BLA submission for Risto‑cel in sickle cell disease by the end of 2026 (possibly early 2027) and ongoing recruitment of the approval‑relevant cohort for BEAM‑302 (alpha‑1‑antitrypsin deficiency). An active IND is in place for BEAM‑304 (PKU) and patient screening is planned to start by the end of 2026; BEAM‑301 (GSD1a) could yield first human data in 2026. Management emphasized the platform‑based development approach, agreed regulatory collaboration with the FDA, and funding intended to support operations through mid‑2029. » More on de.investing.com
Beam Therapeutics reports progress in base editing, alpha‑1 program shows durable effect

Beam Therapeutics presented clinical progress of its base‑editing platform at the Wells Fargo Healthcare Conference, notably with BEAM‑302 for alpha‑1 antitrypsin deficiency, which produced AAT levels above the protective threshold in all patients and durability beyond 18 months. Safety events were mostly limited to reversible liver enzyme elevations; there were no signs of liver injury or hospitalization. The company is advancing programs for sickle cell disease (Risto‑Cel, BLA plan by year‑end), PKU (BEAM‑304 IND cleared) and GSD1A, and expects multiple milestones in the next 12–18 months. A $500 million financing facility from Sixth Street is intended to support commercialization of the sickle cell therapy, while competition in the alpha‑1 field is increasing; Beam continues to see a multi‑year lead in base editing. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2013, BEAM THERAPEUTICS DL-,01 has already paid €0.51 in dividends. The last payout was in December 2013.

Financials

In the last quarter, BEAM THERAPEUTICS DL-,01 had revenue of €429.34k and net profit of -€107.49m

(EUR)	June 2026	YoY
Revenue	429.34k	94.02%
Gross profit	429.34k	100.54%
Net profit	-107.49m	23.86%
EBITDA	-109.54m	33.45%

Fundamentals

Metric	Value
Market capitalization	€2.16bn
Number of shares	102.88m
52-week high/low	€33.00 - €16.88
Dividends	No
Beta	2.23
P/E ratio	-29.72
PEG ratio	-0.40
P/B ratio	2.38
P/S ratio	16.07

Company profile

Beam Therapeutics Inc. ist ein Biotechnologieunternehmen, das genetische Präzisionsarzneimittel für Patienten mit schweren Krankheiten in den Vereinigten Staaten entwickelt. Das Unternehmen entwickelt BEAM-101 zur Behandlung der Sichelzellkrankheit und der Beta-Thalassämie, BEAM-102 zur Behandlung der Sichelzellkrankheit und BEAM-201, eine allogene chimäre Antigenrezeptor-T-Zelle zur Behandlung der rezidivierenden/refraktären akuten lymphoblastischen T-Zell-Leukämie, sowie BEAM-301, einen auf die Leber ausgerichteten Entwicklungskandidaten für die Behandlung von Patienten mit Glykogenspeicherkrankheit Typ Ia. Darüber hinaus entwickelt das Unternehmen Therapien für Alpha-1-Antitrypsin-Mangel, Augenkrankheiten und andere Erkrankungen der Leber, der Muskeln und des zentralen Nervensystems. Das Unternehmen unterhält eine Allianz mit dem Boston Children's Hospital, ein Kooperationsabkommen mit Magenta Therapeutics, Inc. für Forschung und klinische Studien, ein Lizenzabkommen mit Sana Biotechnology, Inc. und eine Forschungskooperation mit dem Institute of Molecular and Clinical Ophthalmology Basel. Es hat auch eine Forschungskooperation mit Pfizer Inc. und Apellis Pharmaceuticals, Inc. sowie eine Kooperations- und Lizenzvereinbarung mit Verve Therapeutics, Inc. Das Unternehmen wurde im Jahr 2017 gegründet und hat seinen Sitz in Cambridge, Massachusetts.

Name	BEAM THERAPEUTICS DL-,01
CEO	John Evans
Headquarters	Cambridge, ma USA
Website	beamtx.com
Sector	Consumer Staples
Industry	Food Products
IPO	06/02/2020
Employees	540